September 22, 2022 07:17 AM EDTUpdated October 18, 01:35 PM

Updated: Eli Lilly's RET drug notches tumor-agnostic accelerated approval, full FDA OK in NSCLC

Amber Tong

Eli Lilly has won a new accelerated approval for its tumor-agnostic RET drug, and managed to convert another accelerated approval to a full approval after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Eli Lilly's RET drug notches tumor-agnostic accelerated approval, full FDA OK in NSCLC

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

FDA OKs the first-ever self-administered vaccine, for flu

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Breaking down silos with a new quantitative approach to drug development

Up­dat­ed: Eli Lil­ly's RET drug notch­es tu­mor-ag­nos­tic ac­cel­er­at­ed ap­proval, full FDA OK in NSCLC

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: Eli Lilly's RET drug notches tumor-agnostic accelerated approval, full FDA OK in NSCLC